Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD The study will enrol up to 36 adult subjects at multiple sites in North America Study strengthens NST’s position as a multi-asset, clinical stage company Amsterdam, The Netherlands,...
Study results identify NASH patients with Type 2 Diabetes as the key target population for Icosabutate therapy − ICONA study assessed the safety, tolerability and efficacy of Icosabutate, a novel, dual FFAR1/FFAR4 (GPR40/GPR120) agonist in NASH patients with F1-F3...
– RPD designation underscores critical need for novel therapies to address IFALD Amsterdam, The Netherlands, October 17 — NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic...
– NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform – Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expected in Q1 2023 – Phase 1 trial with...
Former Pfizer Internal Medicine CSO joins the Boardas an independent board member Amsterdam, The Netherlands, 21 December 2022 – NorthSea Therapeutics B.V. (‘NST’), a biotech company developing novel and innovative strategies for the treatment of...
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated liver disease (IFALD) SEFA-6179 is NST’s third programme to enter...
